References

Amendola, M., Venneri, M. A., Biffi, A., Vigna, E., & Naldini, L. (2005). Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. *Nature Biotechnology, 23*(1), 108-116. https://doi.org/10.1038/nbt1049

Benmebarek, M.-R., Karches, C. H., Cadilha, B. L., Lesch, S., Endres, S., & Kobold, S. (2019). Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. International Journal of Molecular Sciences, 20(6), 1283. https://doi.org/10.3390/ijms20061283

Cappell, K. M., & Kochenderfer, J. N. (2021). A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nature reviews Clinical oncology, 18(11), 715-727. https://doi.org/10.1038/s41571-021-00530-z

Globerson, A., Rawet, M., Waks, T., Horn, G., Ninio-Many, L., Deshet Unger, N., & Eshhar, Z. (2020). Treatment of multiple myeloma using chimeric antigen receptor T cells with dual specificity. Cancer immunology research, 8(12), 1485-1495. https://doi.org/10.1158/2326-6066.CIR-20-0118

Khaniya, A., Rad, S. A. H., Halpin, J., Tawinwung, S., McLellan, A., Suppipat, K., & Hirankarn, N. (2024). Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system. *Journal for Immunotherapy of Cancer, 12*(4). https://doi.org/10.1136/jitc-2023-008555

Leyfman, Y. (2018). Chimeric antigen receptors: unleashing a new age of anti-cancer therapy. Cancer cell international, 18, 1-6. https://doi.org/10.1186/s12935-018-0685-x

Lindner, S. E., Johnson, S. M., Brown, C. E., & Wang, L. D. (2020). Chimeric antigen receptor signaling: Functional consequences and design implications. Science advances, 6(21), eaaz3223. https://doi.org/10.1126/sciadv.aaz3223

Liu, Z., Chen, O., Wall, J. B. J., Zheng, M., Zhou, Y., Wang, L., & Liu, J. (2017). Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. *Scientific Reports, 7*(1), 2193. https://doi.org/10.1038/s41598-017-02460-2

Milone, M. C., Xu, J., Chen, S. J., Collins, M. A., Zhou, J., Powell Jr, D. J., & Melenhorst, J. J. (2021). Engineering-enhanced CAR T cells for improved cancer therapy. Nature cancer, 2(8), 780-793. https://doi.org/10.1038/s43018-021-00277-7

Miliotou, A. N., & Papadopoulou, L. C. (2018). CAR T-cell therapy: a new era in cancer immunotherapy. Current pharmaceutical biotechnology, 19(1), 5-18. https://doi.org/10.2174/1389201019666180418095526

Montalvo, M. J., Bandey, I. N., Rezvan, A., Wu, K.-L., Saeedi, A., Kulkarni, R., Li, Y., An, X., Sefat, K. M. S. R., & Varadarajan, N. (2024). Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. Cell Death & Disease, 15(2), 1–14. https://doi.org/10.1038/s41419-024-06461-8

Sadelain, M., Brentjens, R., & Riviere, I. (2014). The basic principles of chimeric antigen receptor (CAR) design. *Cancer Discovery, 3*(4), 388–98. https://doi.org/10.1158%2F2159-8290.CD-12-0548

Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: current limitations and potential strategies. Blood cancer journal, 11(4), 69. https://doi.org/10.1038/s41408-021-00459-7

Shibuta, M. K., Matsuoka, M., & Matsunaga, S. (2019). 2A peptides contribute to the co-expression of proteins for imaging and genome editing. *Cytologia, 84*(2), 107-111. https://doi.org/10.1508/cytologia.84.107

Sun, H., Zhou, N., Wang, H., Huang, D., & Lang, Z. (2017). Processing and targeting of proteins derived from polyprotein with 2A and LP4/2A as peptide linkers in a maize expression system. *PLoS ONE*, *12*(3), e0174804. https://doi.org/10.1371/journal.pone.0174804

Turtle, C. J., Hanafi, L. A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., & Maloney, D. G. (2016). CD19 CAR–T cells of defined CD4+: CD8+ composition in adult B cell ALL patients. *The Journal of Clinical Investigation, 126(*6), 2123-2138. https://doi.org/10.1172/JCI85309

Vairy, S., Garcia, J. L., Teira, P., & Bittencourt, H. (2018). CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. *Drug Design, Development and Therapy*, 3885-3898. http://dx.doi.org/10.2147/DDDT.S138765

Xie, B., Li, Z., Zhou, J., & Wang, W. (2022). Current status and perspectives of dual-targeting chimeric antigen receptor T-cell therapy for the treatment of hematological malignancies. Cancers, 14(13), 3230. https://doi.org/10.3390/cancers14133230

Yang, X., Cheng, A., Wang, M., Jia, R., Sun, K., Pan, K., Yang, Q., Wu, Y., Zhu, D., Chen, S., Liu, M., Zhao, X.-X., & Chen, X. (2017). Structures and Corresponding Functions of Five Types of Picornaviral 2A Proteins. Frontiers in Microbiology, 8. https://doi.org/10.3389/fmicb.2017.01373

Zhang, C., Hu, Y., Xiao, W., & Tian, Z. (2021). Chimeric antigen receptor-and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cellular & Molecular Immunology, 18(9), 2083-2100. https://doi.org/10.1038/s41423-021-00732-

Zhu, X., Ricci-Tam, C., Hager, E. R., & Sgro, A. E. (2023). Self-cleaving peptides for expression of multiple genes in Dictyostelium discoideum. Plos one, 18(3), e0281211. https://doi.org/10.1371/journal.pone.0281211